-transparent.png){kind=logo}
In order to evaluate kidney tolerance of fleroxacin, a new fluoroquinolone, we performed a volunteer study with 16 healthy males, 20-27 years old. On three consecutive days 800 mg of fleroxacin was administered orally. Alanine-aminopeptidase and distal- and pan-tubular antigens were determined in 24 h urine collections with specific monoclonal antibodies. Routine haematological and biochemical parameters were determined daily and were in the normal range during the follow-up. No significant changes in excretion of alanine-aminopeptidase and of the urinary antigens were observed during the three days of fleroxacin administration and on the following three days. The results obtained in this volunteer study indicate that fleroxacin has no nephrotoxic side effects.
A W Mondorf, and
A Buch, and
G Steinbacher, and
C Rüdel, and
F W Falkenberg
October 1988,
The Journal of antimicrobial chemotherapy,
A W Mondorf, and
A Buch, and
G Steinbacher, and
C Rüdel, and
F W Falkenberg
July 1989,
Journal of chemotherapy (Florence, Italy),
A W Mondorf, and
A Buch, and
G Steinbacher, and
C Rüdel, and
F W Falkenberg
October 1988,
The Journal of antimicrobial chemotherapy,
A W Mondorf, and
A Buch, and
G Steinbacher, and
C Rüdel, and
F W Falkenberg
December 1992,
Antimicrobial agents and chemotherapy,
A W Mondorf, and
A Buch, and
G Steinbacher, and
C Rüdel, and
F W Falkenberg
October 1988,
The Journal of antimicrobial chemotherapy,
A W Mondorf, and
A Buch, and
G Steinbacher, and
C Rüdel, and
F W Falkenberg
January 1998,
Chemotherapy,
A W Mondorf, and
A Buch, and
G Steinbacher, and
C Rüdel, and
F W Falkenberg
January 1981,
Arzneimittel-Forschung,
A W Mondorf, and
A Buch, and
G Steinbacher, and
C Rüdel, and
F W Falkenberg
January 1995,
Drugs,
A W Mondorf, and
A Buch, and
G Steinbacher, and
C Rüdel, and
F W Falkenberg
August 2000,
Biological & pharmaceutical bulletin,
A W Mondorf, and
A Buch, and
G Steinbacher, and
C Rüdel, and
F W Falkenberg
March 1993,
Arzneimittel-Forschung,
